Navigation Links
Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
Date:3/5/2008

YEAR ENDED DECEMBER 31, 2007

Consolidated revenues for the year ended December 31, 2007 were $42.1 million compared to $38.8 million for the same period in 2006. The increase in revenues for 2007 is mainly related to increased sales of Cetrotide(R) and Impavido(R), partly compensated by lower license fees revenues from the Company's partners.

Consolidated R&D costs were $39.2 million for the year ended December 31, 2007 compared to $27.4 million for the same period in 2006. The increase in R&D expenses of $11.8 million in 2007 is mainly related to the advancement of the Company's lead product cetrorelix in Phase 3 for BPH; as well as to further advancement of targeted, earlier-stage development programs including AEZS-108, a cytotoxic conjugate and AEZS-112, a tubulin inhibitor.

Consolidated loss from operations increased to $34.8 million for the year ended December 31, 2007 compared to $23.8 million for the same period in 2006. The increase in loss from operations in 2007 is attributable to a combination of lower license revenues, increase in non-recurring G&A corporate expenses and additional R&D expenses mainly related to the advancement of the Company's Phase 3 program with cetrorelix in BPH. This increase in loss from operations in 2007 was partly offset by increased sales and royalties, as well as lower D&A expenses.

Consolidated net loss was $32.3 million or $0.61 per basic and diluted share for the year ended December 31, 2007 compared to consolidated net earnings of $33.4 million or $0.64 per basic share and $0.62 per diluted share for the same period in 2006. The increased net loss in 2007 is related to a higher loss from operations of nearly $10 million, lower income tax recovery of nearly $27 million related to the recognition of future income tax assets, mainly attributable to the sale of Atrium shares in 2006, and the special distribution of AEterna Zentaris' remaining interest in January 2007, as well as lower net earnings
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
2. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
3. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
4. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
7. AEterna Zentaris Announces Outcome of Managements Strategic Review
8. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
9. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
10. BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
11. MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Aug. 19, 2014 CSSi, the leader in ... announced the formation of the company,s Medical and Clinical ... addition of Dr. William E. Gannon, Jr. ... The MCAB, with Dr. Gannon,s ... therapeutic areas and set strategic goals for the advancement ...
(Date:8/19/2014)... /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or "the Company") ... its Oral Amphotericin B (Oral Amp B) drug ... by ImmuneCarta®, the immune monitoring business unit of ... Oral Amp B in reactivating latent HIV viral ... treatment with antiretroviral therapy. Memory ...
(Date:8/18/2014)... 2014) -- A new therapy developed by researchers ... College of Medicine and Columbia University Medical Center ... interventional cardiovascular disease treatment. , The researchers ... molecular therapy could selectively inhibit blood vessel re-narrowing ... procedure using a balloon catheter to open narrowed ...
(Date:8/18/2014)...   Sterne, Kessler, Goldstein & Fox P.L.L.C. , ... DC , announced today that it has filed ... with the U.S. Patent and Trademark Office (USPTO) on ... Inc. (Nasdaq: BRLI).  These IPR petitions aim to nullify ... Inc. These patents have been asserted against GeneDx in ...
Breaking Biology Technology:CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 2CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 3iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3Selective therapy may improve artery repair after interventional cardiovascular procedures 2Selective therapy may improve artery repair after interventional cardiovascular procedures 3Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 2Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 3
... Cephalon, Inc. (Nasdaq:,CEPH) today announced that it ... a lawsuit in U.S. District Court in Delaware ... Laboratories,Inc., for infringement of U.S. Patent Nos. 6,200,604 ... Cephalon product FENTORA(R) (fentanyl buccal,tablet) [C-II]. The 6,200,604 ...
... iCAD, Inc. (Nasdaq:,ICAD), an industry-leading provider of Computer-Aided ... Executive Officer, and,Darlene Deptula-Hicks, Executive Vice President and ... corporate update at the Seventh Annual,Needham and Company ... 2008 at 2:00 p.m., (Eastern Daylight Time) at ...
... changes and further organizational ... consolidation ... Paul LaViolette to retire ... that President and Chief Executive,Officer Jim Tobin will be extending his tenure at the Company. The ...
Cached Biology Technology:Cephalon Files Patent Infringement Lawsuit Against Watson Pharmaceuticals 2Cephalon Files Patent Infringement Lawsuit Against Watson Pharmaceuticals 3iCAD to Present at Seventh Annual Needham and Company Biotechnology and Medical Technology Conference 2Boston Scientific Announces CEO Jim Tobin to Extend Tenure 2Boston Scientific Announces CEO Jim Tobin to Extend Tenure 3Boston Scientific Announces CEO Jim Tobin to Extend Tenure 4Boston Scientific Announces CEO Jim Tobin to Extend Tenure 5
(Date:8/20/2014)... who have suffered concussions ready to return to action? ... high school athletes who head back on the field ... regression in their abilities to simultaneously walk and do ... changes in their balance and/or altered walking speed, was ... 12 had returned to activity in less than a ...
(Date:8/20/2014)... spiciness that is irresistible to some, but intolerable to ... their findings to develop a new drug candidate for ... inflammation or other problems. They reported their progress on ... in ACS, Journal of Medicinal Chemistry . , ... had pegged a compound called capsaicin as the active ...
(Date:8/20/2014)... Your chairs, synthetic rugs and plastic bags could one ... waste rather than petroleum, scientists are now reporting. The ... help the world deal with its agricultural and plastic ... . , Athanassia Athanassiou, Ilker S. Bayer and colleagues ... plastic,s popularity is constantly growing. In 2012, its production ...
Breaking Biology News(10 mins):Recovery reversal seen in Oregon study of returning concussed athletes 2Recovery reversal seen in Oregon study of returning concussed athletes 3
... Center for Climate Change (BC3) has analysed the expected economic impact ... the Kyoto Protocol for the period 2008-2012 and for the phase ... come out on top in comparison to sectors such as industrial ... Spain have an impact on the economy, in other words, making ...
... (VBI) at Virginia Tech have constructed a mathematical and ... to simulate the cellular and molecular changes underlying chronic ... to explore different interactions of cells in the immune ... in the colon, and identify intervention points to perhaps ...
... HOUSTON -- A novel approach detects genetically abnormal cells in ... abnormalities found in tumor cells and increase in number with ... scientists at The University of Texas MD Anderson Cancer Center ... Lung cancer patients in the study also had many times ...
Cached Biology News:CO2 reduction policies in Spain strengthen the services sector 2Math model of colon inflammation singles out dangerous immune cells 2Math model of colon inflammation singles out dangerous immune cells 3UT MD Anderson study ties abnormal cells in blood to lung cancer 2UT MD Anderson study ties abnormal cells in blood to lung cancer 3
Request Info...
Guinea Pig Complement...
Collected from 8-12 week-old New Zealand or Californian rabbits....
Enables rapid purification of double-stranded DNA fragments = 200 bp, including, for example, PCR reaction products, DNA fragments obtained in restriction enzyme digests, or double-stranded cDNA...
Biology Products: